Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects
- First Online:
- Cite this article as:
- Bolton, A.E., Peng, B., Hubert, M. et al. Cancer Chemother Pharmacol (2004) 53: 102. doi:10.1007/s00280-003-0722-9
- 448 Downloads
This study was carried out to investigate the influence of CYP3A induction with rifampicin on imatinib (Gleevec) exposure.
The study employed a single center, single-sequence design. A group of 14 healthy male and female subjects received imatinib as a single 400 mg oral dose on two occasions: on study day 1 and on study day 15. Rifampicin treatment (600 mg once daily) for CYP4503A induction was initiated on study day 8 and maintained until day 18. Imatinib pharmacokinetics were determined up to 96 h after dosing on day 1 (no induction) and on days 15–18 (during concomitant rifampicin). Plasma concentrations of imatinib and its main metabolite CGP74588 were determined using a LC/MS/MS method. The ratio of 6β-hydroxycortisol to cortisol excreted in the urine was measured to monitor the induction of CYP3A.
During concomitant rifampicin administration, the mean imatinib Cmax, AUC0–24 and AUC0–∞ decreased by 54% (90% CI: 48–60%), 68% (64–70%) and 74% (71–76%), respectively. The increase in clearance (Cl/f) was 385% (348–426%) during rifampicin treatment. The mean Cmax and AUC0–24 of the metabolite CGP74588 increased by 88.6% (68.3%–111.4%) and 23.9% (13.5%–35.2%) after rifampicin pretreatment. However, the AUC0–∞ decreased by 11.7% (3.3–19.4%). All subjects demonstrated a marked induction of hepatic microsomal CYP3A analyzed by the excretion ratio of 6β-hydroxycortisol to cortisol from a mean baseline concentration of 5.6 U to 50.5 U.
Concomitant use of imatinib and rifampicin or other potent inducers of CYP4503A may result in subtherapeutic plasma concentrations of imatinib. In patients in whom rifampicin or other CYP3A inducers are prescribed, alternative therapeutic agents with less potential for enzyme induction should be selected.